02/16/2026
https://www.facebook.com/share/1GMaX1P3EV/?mibextid=wwXIfr
In January 1922, inside a Toronto hospital ward, rows of children lay weakened by diabetic ketoacidosis. Their breathing was labored and sweet with the smell doctors had come to recognize as a sign of uncontrolled diabetes. Many were emaciated, drifting in and out of consciousness. Parents stood nearby, aware that a diagnosis of what we now call Type 1 diabetes almost always ended in death. Until then, treatment consisted mainly of severe dietary restriction, which could delay but not prevent the fatal outcome.
That winter, a small research team arrived carrying a new extract prepared from animal pancreases. The group included Frederick Banting and Charles Best, working under the supervision of John Macleod at the University of Toronto. A biochemist, James Collip, had helped refine the substance to make it safer for human use. They called it insulin.
The first patient to receive the extract was a fourteen year old boy named Leonard Thompson. The initial injection earlier in January produced limited improvement and some side effects because the preparation was still impure. After further refinement by Collip, a second series of injections was administered. This time, the results were unmistakable. Blood sugar levels fell. Ketones decreased. The boy’s condition stabilized.
As word spread through the hospital, other children in critical condition were treated. Nurses observed breathing patterns improve. Comas lifted. Children who had been near death began to regain strength over days and weeks. The transformation was not instantaneous, nor was it free of complications, but the change was profound. For the first time, physicians had a therapy that addressed the underlying metabolic disorder rather than merely slowing its progress.
The impact extended beyond a single ward. Within a year, insulin production was scaled up through collaboration with pharmaceutical manufacturers. In 1923, Banting and Macleod were awarded the Nobel Prize in Physiology or Medicine, which they shared with Best and Collip in recognition of the team effort. Insulin quickly became a standard treatment worldwide, altering the life expectancy of people with Type 1 diabetes.
The episode marked a shift in modern medicine. It demonstrated how laboratory research, clinical testing, and hospital care could converge to produce rapid therapeutic change. It also underscored ethical responsibility. Early patients and families consented to an experimental treatment in circumstances of extreme risk. Their participation shaped the future of endocrinology.
A century later, insulin remains essential for millions of people. Its formulations have improved, delivery methods have evolved, and monitoring technologies have advanced. Yet debates about cost and access continue. The events of 1922 remind us that medical breakthroughs are not abstract achievements. They unfold in hospital rooms, among families confronting loss, and through collaboration among scientists and clinicians.
In that Toronto ward, despair met discovery. The children who opened their eyes after receiving insulin did more than survive. They marked the beginning of a new era in chronic disease management. Each dose administered today traces its lineage to that winter, when research crossed into practice and altered the course of countless lives.
